Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Intima Bioscience, Inc.
M.D. Anderson Cancer Center
Essen Biotech
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
TCRCure Biopharma Ltd.
University of California, Irvine
TCR2 Therapeutics
TCR2 Therapeutics
Qingdao Sino-Cell Biomedicine Co., Ltd.
University of Pittsburgh
Immatics US, Inc.
Vall d'Hebron Institute of Oncology
Acepodia Biotech, Inc.
Essen Biotech
National Institutes of Health Clinical Center (CC)
BioEclipse Therapeutics
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Fred Hutchinson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Fate Therapeutics
BGI, China
Genocea Biosciences, Inc.
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Guangzhou Institute of Respiratory Disease
Shenzhen Second People's Hospital